Lacidipine

CLINICAL USE

Calcium-channel blocker:Hypertension

DOSE IN NORMAL RENAL FUNCTION

2–6 mg once daily

PHARMACOKINETICS

Molecular weight :455.5

%Protein binding :95

%Excreted unchanged in urine : 0

Volume of distribution (L/kg) :0.9–2.3

half-life – normal/ESRD (hrs) :13–19/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unknown dialysability. Dose as in normal renal function

HD :Unknown dialysability. Dose as in normal renal function

HDF/high flux :Unknown dialysability. Dose as in normal renal function

CAV/VVHD :Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Anaesthetics: enhanced hypotensive effect

Anti-epileptics: effect possibly reduced by carbamazepine, barbiturates, phenytoin and primidone

Antifungals: metabolism possibly inhibited by itraconazole and ketoconazoleAntihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of post-synaptic alpha-blockers

Antivirals: concentration possibly increased by ritonavir

Ciclosporin: 10 kidney transplant patients on ciclosporin, prednisone and azathioprine were given 4 mg lacidipine daily. A very small increase in the trough serum levels (+6%) and AUC (+14%) of the ciclosporin occurred

Grapefruit juice: concentration increased – avoid concomitant useTheophylline: possibly increased theophylline concentration

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–.

Tags: post-by-auto-php